| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2007
Brian Lawler |
Renovis Tries to Right Itself Renovis takes some steps to try and recover after its lead drug fails in clinical testing. Investors, take note.   |
The Motley Fool
June 11, 2007
Brian Lawler |
Renovis Is Still Around The drug developer continues work on its preclinical compounds. The company stands out among the drugmakers who have released failed studies over the past 12 months because its management hasn't tried to string investors along about its failed stroke study. |
The Motley Fool
December 1, 2008
Brian Orelli |
It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies. |
BusinessWeek
December 29, 2003
Gene G. Marcial |
Faster Pulse At Esperion Esperion Therapeutics shares may zip up, says Mark Monane of investment firm Needham. Pfizer, Genentech, or Aventis could strike a deal for any of Esperion's four cardiovascular drugs now in trials, he says. |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here. |
The Motley Fool
October 26, 2006
Brian Lawler |
Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results. |
The Motley Fool
August 3, 2006
S.J. Caplan |
AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future. |
The Motley Fool
September 26, 2007
Brian Lawler |
Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures. |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
BusinessWeek
November 19, 2007
Catherine Arnst |
A Top Gun Takes Aim at Strokes Jackson Streeter left his dream job as a fighter pilot to tackle stokes, the second leading cause of death. |
The Motley Fool
July 27, 2006
Stephen D. Simpson |
AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain. |
BusinessWeek
December 29, 2010
Kelley & Cortez |
AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs. |
The Motley Fool
May 11, 2009
Brian Orelli |
Brilliant, Now Let's See the Data AstraZeneca's investors today should be cautiously optimistic about Brilinta. It could be a blockbuster for the company, but it may need some brilliant marketing to compete. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
The Motley Fool
February 29, 2008
Brian Orelli |
Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years. |
BusinessWeek
October 17, 2005
Gene G. Marcial |
Encysive Is Breathing Easy Among biotechs favored by Mark Monane of investment firm Needham is Encysive Pharmaceuticals. |
The Motley Fool
April 2, 2008
Brian Lawler |
Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug. |
The Motley Fool
January 27, 2005
Stephen D. Simpson |
AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer. |
Nutrition Action Healthletter
September 2001 |
Brain Attack: What you need to know about stroke... |
The Motley Fool
October 14, 2010
Sean Williams |
Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away. |
BusinessWeek
January 31, 2005
Kerry Capell |
No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker. |
Chemistry World
December 24, 2015
Jennifer Newton |
AstraZeneca to buy Acerta for blood cancer drug AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here. |
The Motley Fool
February 5, 2007
Billy Fisher |
A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007. |
The Motley Fool
October 30, 2009
Brian Orelli |
Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
BusinessWeek
February 9, 2004
Gene G. Marcial |
Telik's Promising Tumor Treatments Telik, which develops drugs for cancer -- mainly chemotherapy-resistant solid tumors -- and diabetes may be the next biotech buyout. So says Mark Monane of investment outfit Needham, who identified Esperion Therapeutics in early December as buyout bait. |
Nursing
May 2009
Miller & Mink |
Acute Ischemic Stroke: Not a Moment to Lose A review of the guidelines for acute ischemic stroke care for adults, based on the most recent revisions. Plus, a look at the two types of strokes. |
The Motley Fool
April 30, 2010
Brian Orelli |
Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter. |
Nursing Management
June 2010
Alison Trembly |
Stroke care in the 21st century Stroke care has changed dramatically in the last decade. This story emphasizes several key points about stroke in the 21st century. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
